Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

被引：0
|
作者：
Jinlin Song
Qiufei Ma
Wei Gao
Ze Cong
Jipan Xie
Zachary Zimmerman
Laura Belton
Janet Franklin
Stephen Palmer
机构：
[1] Analysis Group,
[2] Inc.,undefined
[3] Amgen Inc.,undefined
[4] Analysis Group,undefined
[5] Inc.,undefined
[6] LB Biostatistics,undefined
[7] Centre for Health Economics,undefined
[8] University of York,undefined
来源：
Advances in Therapy | 2019年 / 36卷
关键词：
Blinatumomab; Complete remission; Inotuzumab ozogamicin; Matching-adjusted indirect comparison; Overall survival; Relapsed or refractory acute lymphoblastic leukemia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：950 / 961
页数：11
相关论文
共 50 条
  • [31] Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
    Chen, Joseph
    Haughey, May
    Vandendries, Erik
    DeAngelo, Daniel J.
    Kantarjian, Hagop M.
    Ruiz-Garcia, Ana
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (01): : 184 - 193
  • [32] Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia
    Thota, Swapna
    Advani, Anjali
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 98 (05) : 425 - 434
  • [33] Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia
    Badar, Talha
    Szabo, Aniko
    Dinner, Shira
    Liedtke, Michaela
    Burkart, Madelyn
    Shallis, Rory M.
    Yurkiewicz, Ilana R.
    Kuo, Eric
    Khan, Muhammad Ali
    Balasubramanian, Suresh
    Yang, Jay
    Hefazi, Mehrdad
    Podoltsev, Nikolai
    Patel, Anand
    Curran, Emily
    Wang, Amy
    Arslan, Shukaib
    Aldoss, Ibrahim
    Siebenaller, Caitlin
    Mattison, Ryan J.
    Litzow, Mark R.
    Wadleigh, Martha
    Advani, Anjali S.
    Atallah, Ehab
    CANCER, 2021, 127 (07) : 1039 - 1048
  • [34] MATCHING-ADJUSTED INDIRECT COMPARISON OF IXEKIZUMAB VS. TOFACITINIB IN PSORIATIC ARTHRITIS
    Sapin, C.
    Panni, T.
    Meszaros, G.
    Hill, J.
    Hartz, S.
    VALUE IN HEALTH, 2020, 23 : S593 - S593
  • [35] Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia
    Contreras, Cristina F.
    Higham, Christine S.
    Behnert, Astrid
    Kim, Kailyn
    Stieglitz, Elliot
    Tasian, Sarah K.
    PEDIATRIC BLOOD & CANCER, 2021, 68 (01)
  • [36] Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain
    Torrent, Anna
    Morgades, Mireia
    Garcia-Calduch, Olga
    de Llano, Maria Paz Queipo
    Montesinos, Pau
    Navarro, Irene
    Hernandez-Rivas, Jesus Maria
    Barez-Garcia, Abelardo
    Gonzalez-Campos, Jose
    Oiartzabal, Itziar
    Valero, Marta
    Cervera, Marta
    Zudaire, Teresa
    Albors-Ferreiro, Manuel
    Lopez-Godino, Oriana
    Gil-Cortes, Cristina
    Villalon, Lucia
    Saldana, Raquel
    Ribera, Josep-Maria
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (03) : 485 - 490
  • [37] Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma
    Garrett, May
    Ruiz-Garcia, Ana
    Parivar, Kourosh
    Hee, Brian
    Boni, Joseph
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2019, 46 (03) : 211 - 222
  • [38] A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
    Brivio, Erica
    Hoogendijk, Raoull
    Chantrain, Christophe
    Rialland, Fanny
    Contet, Audrey
    Elitzur, Sarah
    Dalla-Pozza, Luciano
    Kallay, Krisztian
    Li, Chi Kong
    Kato, Motohiro
    Markova, Inna V.
    Schmiegelow, Kjeld
    Bodmer, Nicole
    Pieters, Rob
    Zwaan, Christian Michel
    BLOOD, 2019, 134
  • [39] The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia
    Yilmaz, Musa
    Richard, Samantha
    Jabbour, Elias
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2015, 6 (05) : 253 - 261
  • [40] Results of the Compassionate Program of Inotuzumab Ozogamicin for Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia in Spain
    Ribera, Josep-Maria
    Garcia, Olga
    Montesinos, Pau
    Rodriguez-Veiga, Rebeca
    Garcia-Fortes, Maria
    Barez Garcia, Abelardo
    Oiartzabal, Itziar
    Gonzalez-Campos, Jose A.
    Mendez Sanchez, Jose Angel
    Zudaire, Maite
    Villalon, Lucia
    Lopez-Godino, Oriana
    Gil, Cristina
    Vicent, Ana
    Saldana, Raquel
    Valero, Marta
    Torrent, Anna
    Maria Hernandez-Rivas, Jesus
    BLOOD, 2021, 138
12345